Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q1 2026 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2025 Net Income-$19.63M-$19.63MN/M vs Q1 2025 EPS Diluted-$1.69-$1.69N/M vs Q1 2025 Operating Income-$20,436,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
Free Cash Flowderived-$16,095,000N/M ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end